Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, debilitating, and relapsing rare skin disease affecting approximately 27,000 adults in the US whose disease is uncontrolled by systemic corticosteroids Dupixent is now approved in the US to treat eight distinct diseases with underlying type 2 inflammation, including diseases of the skin, gut, and respiratory system that affect a broad range of patients, from infants to elderly people Paris and Tarrytown, NY, June 20, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP).
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints
![]() RGO 11 Aug 2022 Paid | Other | €0 Per Share |
![]() RGO 15 Jul 2021 Paid | Other | €0 Per Share |
30 Jul 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
29 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | - Cons. EPS | - EPS |
31 Oct 2024 Date | | - Cons. EPS | - EPS |
![]() RGO 11 Aug 2022 Paid | Other | €0 Per Share |
![]() RGO 15 Jul 2021 Paid | Other | €0 Per Share |
30 Jul 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
29 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | - Cons. EPS | - EPS |
31 Oct 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Dr. Leonard S. Schleifer M.D., Ph.D. CEO | XFRA Exchange | US75886F1075 ISIN |
US Country | 15,158 Employees | - Last Dividend | - Last Split | 2 Apr 1991 IPO Date |
Regeneron Pharmaceuticals, Inc. is a biotechnology firm that is renowned for its dedication to discovering, inventing, developing, manufacturing, and commercializing medicines to combat a variety of diseases globally. Since its inception in 1988, the company has been at the forefront of innovative treatments, striving to address the unmet medical needs of patients around the world. With its headquarters nested in Tarrytown, New York, Regeneron has made a significant impact in the pharmaceutical industry by delivering life-changing medicines to patients in need.
Regeneron Pharmaceuticals, Inc. offers a diverse portfolio of products aimed at treating a wide range of diseases, including but not limited to, eye diseases, allergies and inflammations, cardiovascular and metabolic conditions, infectious diseases, rare diseases, cancers, pain, and hematologic conditions.
In addition to these products, Regeneron is continuously working on developing new treatments for a variety of diseases, demonstrating their commitment to innovation and improving patient health worldwide.